Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 3:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 421 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Metformin Placebo Clear all
Active, not recruiting Phase 2 Interventional

Glycemic Regulation as Endometriosis Adjunct Treatment

NCT06611501
View directory record Official record
Conditions
Pelvic Pain, Endometriosis
Interventions
Metformin Hydrochloride, Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
15 Years to 35 Years · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 30, 2026, 3:49 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of S-707106 in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control With Metformin Therapy

NCT01240759
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
S-707106 Dose A, S-707106 Dose B, S-707106 Dose C, Placebo A tablet, Metformin
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 75 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Sep 30, 2026, 3:49 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Endogenous Opioid Activity and Affective State in Insulin Resistant Women

NCT02069379
View directory record Official record
Conditions
Depression, Insulin Resistance, Metabolic Syndrome
Interventions
Metformin, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 8, 2018 · Synced Sep 30, 2026, 3:49 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin

NCT03066830
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Sotagliflozin (SAR439954), Placebo, Metformin, Sulfonylurea
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
28
States / cities
Litchfield Park, Arizona • Peoria, Arizona • Greenbrae, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Sep 30, 2026, 3:49 PM EDT
Completed Phase 4 Interventional Results available

Ranolazine and Microvascular Angina by PET in the Emergency Department

NCT02052011
View directory record Official record
Conditions
Microvascular Angina
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
30 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Sep 30, 2026, 3:49 PM EDT
Completed Phase 3 Interventional Results available

A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes

NCT02681094
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Inadequate Glycaemic Control
Interventions
Dapagliflozin, Placebo for Dapagliflozin, Saxagliptin, Placebo for Saxagliptin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
905 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
48
States / cities
Saraland, Alabama • Fresno, California • Harbor City, California + 41 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Sep 30, 2026, 3:49 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes

NCT01023581
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Alogliptin, Metformin, Alogliptin Placebo, Metformin Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
784 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
109
States / cities
Dothan, Alabama • Muscle Shoals, Alabama • Pell City, Alabama + 106 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2013 · Synced Sep 30, 2026, 3:49 PM EDT
Completed Phase 3 Interventional Results available

A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise

NCT00528372
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Dapagliflozin placebo, Metformin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
1,067 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
38
States / cities
Phoenix, Arizona • Tempe, Arizona • Fresno, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2015 · Synced Sep 30, 2026, 3:49 PM EDT
Completed Phase 4 Interventional Results available

The Effect of Welchol on Glucose Metabolism in Type 2 Diabetics

NCT00951899
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Colesevelam, Placebo, Diet, Metformin
Drug · Other · Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years to 70 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 11, 2013 · Synced Sep 30, 2026, 3:49 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Metformin for the Treatment of Microvascular Dysfunction After Gestational Diabetes

NCT05917587
View directory record Official record
Conditions
Gestational Diabetes
Interventions
Metformin Hydrochloride, placebo
Drug · Other
Lead sponsor
Anna Stanhewicz, PhD
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Sep 30, 2026, 3:49 PM EDT
Completed Phase 2 Interventional Results available

Castration Compared to Castration Plus Metformin as First Line Treatment for Patients With Advanced Prostate Cancer

NCT01620593
View directory record Official record
Conditions
Prostate Cancer
Interventions
Placebo, Metformin
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Sep 30, 2026, 3:49 PM EDT
Completed Phase 2 Interventional Results available

Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes

NCT01923181
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
semaglutide, oral placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
632 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
40
States / cities
Tucson, Arizona • Chula Vista, California • Long Beach, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2021 · Synced Sep 30, 2026, 3:49 PM EDT
Completed Not applicable Interventional

Placebo-Controlled Clinical Nutrition Study of the Safety and Metabolic Effects of Two Medical Foods in Type 2 Diabetes

NCT03893422
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
WB-010, WB-011, Placebo
Other
Lead sponsor
Pendulum Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Torrance, California • Tustin, California • Youngstown, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Sep 30, 2026, 3:49 PM EDT
Completed Phase 1 Interventional

Single Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes

NCT01105429
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
BMS-820132, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
3
States / cities
Chula Vista, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 9, 2011 · Synced Sep 30, 2026, 3:49 PM EDT
Completed Phase 3 Interventional Results available

The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)

NCT01106677
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, Canagliflozin, Sitagliptin, Metformin immediate release
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
45
States / cities
Little Rock, Arkansas • Fountain Valley, California • National City, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Sep 30, 2026, 3:49 PM EDT
Completed Phase 3 Interventional Results available

Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus

NCT02229383
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Exenatide, Exenatide matching placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
68
States / cities
Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Sep 30, 2026, 3:49 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Metabolic Effect of Metformin in Obese Insulin Resistant Adolescents With Normal Glucose Tolerance

NCT00667498
View directory record Official record
Conditions
Pediatric Obesity, Insulin Resistance, Hyperinsulinemia
Interventions
Metformin, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
13 Years to 17 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 18, 2009 · Synced Sep 30, 2026, 3:49 PM EDT
Completed Phase 2 Interventional Results available

Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance

NCT00443755
View directory record Official record
Conditions
Type 2 Diabetes, Insulin Resistance, Metabolic Syndrome
Interventions
metformin, pioglitazone, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
20 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Sep 30, 2026, 3:49 PM EDT
Terminated Phase 2 Interventional

A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug On Adults With Type 2 Diabetes Mellitus Taking Metformin

NCT02053103
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
PF-05175157, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Sep 30, 2026, 3:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY3556050 in Healthy Participants

NCT04156750
View directory record Official record
Conditions
Healthy
Interventions
LY3556050, Placebo, Iohexol, Metformin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Sep 30, 2026, 3:49 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients

NCT01422876
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
high dose FDC, BI 10773 high dose, high dose FDC placebo, low dose FDC placebo, high dose BI 10773 placebo, low dose FDC, BI 10773 low dose, linagliptin, linagliptin placebo, BI 10773 low dose placebo, low dose BI 10773 placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
112
States / cities
Birmingham, Alabama • Foley, Alabama • Mobile, Alabama + 90 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2015 · Synced Sep 30, 2026, 3:49 PM EDT
Completed Phase 4 Interventional Results available

The Health Influences of Puberty (HIP) Study

NCT01775813
View directory record Official record
Conditions
Obesity, Insulin Resistance, Gonadal Dysfunction, Type 2 Diabetes
Interventions
Metformin, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
9 Years to 17 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Sep 30, 2026, 3:49 PM EDT
Recruiting Phase 2Phase 3 Interventional

Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation

NCT07092618
View directory record Official record
Conditions
Longevity, GLP-1, Geroscience, Aging
Interventions
Metformin, Rapamycin, Naltrexone, Vitamin C
Drug · Dietary Supplement
Lead sponsor
AgelessRx
Industry
Eligibility
40 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Sep 30, 2026, 3:49 PM EDT
Completed Phase 2 Interventional

12 Week Study Of PF-00734200 For The Treatment Of Type 2 Diabetes Mellitus In Subjects Treated With Metformin

NCT00473525
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, PF-00734200 10 mg QD, PF-00734200 20 mg QD, PF-00734200 5 mg QD, PF-00734200 2 mg QD
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
64
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2010 · Synced Sep 30, 2026, 3:49 PM EDT